Parathormone and chronic kidney disease;Parathormone et maladie rénale chronique

Nephrologie et Therapeutique

Volumn 3, Issue 4, 2007, Pages 133-138

  Bacchetta, Justine ^a   Jolivot, Anne ^a   Souberbielle, Jean Claude ^b   Charrié, Anne ^c   Guebre, Fitsum ^a,d   Chauvet, Cécile ^a   Fouque, Denis ^a,d  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Chronic kidney disease; PTH assays; PTH fragments

Indexed keywords

PARATHYROID HORMONE; PEPTIDE FRAGMENT;

BONE BIOPSY; BONE DISEASE; CHRONIC KIDNEY DISEASE; GOLD STANDARD; HORMONE DETERMINATION; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; PARATHYROID HORMONE BLOOD LEVEL; SHORT SURVEY; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; KIDNEY DISEASE; KIDNEY DISTAL TUBULE; PATHOPHYSIOLOGY;

BONE DISEASES; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES, DISTAL; PARATHYROID HORMONE; PEPTIDE FRAGMENTS;

EID: 34447565006     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2007.04.003     Document Type: Short Survey

References (30)

1. Torres P.U., Prie D., Beck L., and Friedlander G. New therapies for uremic secondary hyperparathyroidism. J. Ren. Nutr. 16 2 (2006) 87-99
2. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42 4 Suppl 3 (2003) S1-S201
3. Torres P.U. The need for reliable serum parathyroid hormone measurements. Kidney Int. 70 2 (2006) 240-243
4. Divieti P., John M.R., Juppner H., and Bringhurst F.R. Human PTH 7-84 inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143 1 (2002) 171-176
5. Friedman P.A., and Goodman W.G. PTH 1-84/7-84: a balance of power. Am. J. Physiol. Renal Physiol. 290 5 (2006) F975-F984
6. Gennero I., Moulin P., Edouard T., Conte-Auriol F., Tauber M.T., and Salles J.P. Bone mineral metabolism: recent data and perspectives related to osteogenesis. Arch. Pediatr. 11 12 (2004) 1473-1483
7. D'Amour P., Rakel A., Brossard J.H., Rousseau L., Albert C., and Cantor T. Acute regulation of circulating parathyroid hormone (PTH) molecular forms by calcium: utility of PTH fragments/PTH 1-84 ratios derived from three generations of PTH assays. J. Clin. Endocrinol. Metab. 91 1 (2006) 283-289
8. Marx S.J. Hyperparathyroid and hypoparathyroid disorders. N. Engl. J. Med. 343 25 (2000) 1863-1875
9. Nguyen-Yamamoto L., Rousseau L., Brossard J.H., Lepage R., and D'Amour P. Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142 4 (2001) 1386-1392
10. Tanno Y., Yokoyama K., Nakayama M., Katoh A., Yamamoto H., Iwasaki Y., et al. IRMA (whole PTH) is a more useful assay for the effect of PTH on bone than the Allegro intact PTH assay in CAPD patients with low bone turnover marker. Nephrol. Dial. Transplant. 18 Suppl 3 (2003) iii97-iii98
11. Murray T.M., Rao L.G., Muzaffar S.A., and Ly H. Human parathyroid hormone carboxyterminal peptide (53-84) stimulates alkaline phosphatase activity in dexamethasone-treated rat osteosarcoma cells in vitro. Endocrinology 124 2 (1989) 1097-1099
12. Sutherland M.K., Rao L.G., Wylie J.N., Gupta A., Ly H., Sodek J., et al. Carboxyl-terminal parathyroid hormone peptide (53-84) elevates alkaline phosphatase and osteocalcin mRNA levels in SaOS-2 cells. J. Bone Miner. Res. 9 4 (1994) 453-458
13. Erdmann S., Muller W., Bahrami S., Vornehm S.I., Mayer H., Bruckner P., et al. Differential effects of parathyroid hormone fragments on collagen gene expression in chondrocytes. J. Cell Biol. 135 4 (1996) 1179-1191
14. Sneddon W.B., Syme C.A., Bisello A., Magyar C.E., Rochdi M.D., Parent J.L., et al. Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50). J. Biol. Chem. 278 44 (2003) 43787-43796
15. Huan J., Olgaard K., Nielsen L.B., and Lewin E. Parathyroid hormone 7-84 induces hypocalcemia and inhibits the parathyroid hormone 1-84 secretory response to hypocalcemia in rats with intact parathyroid glands. J. Am. Soc. Nephrol. 17 7 (2006) 1923-1930
16. McKee M.D., and Murray T.M. Binding of intact parathyroid hormone to chicken renal plasma membranes: evidence for a second binding site with carboxyl-terminal specificity. Endocrinology 117 5 (1985) 1930-1939
17. Takasu H., Baba H., Inomata N., Uchiyama Y., Kubota N., Kumaki K., et al. The 69-84 amino acid region of the parathyroid hormone molecule is essential for the interaction of the hormone with the binding sites with carboxyl-terminal specificity. Endocrinology 137 12 (1996) 5537-5543
18. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., and Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104 4 (1999) 439-446
19. Divieti P., Inomata N., Chapin K., Singh R., Juppner H., and Bringhurst F.R. Receptors for the carboxyl-terminal region of PTH 1-84 are highly expressed in osteocytic cells. Endocrinology 142 2 (2001) 916-925
20. Salusky I.B., and Juppner H. New PTH assays and renal osteodystrophy. Pediatr. Nephrol. 19 7 (2004) 709-713
21. Herberth J., Fahrleitner-Pammer A., Obermayer-Pietsch B., Krisper P., Holzer H., Malluche H.H., et al. Changes in total parathyroid hormone (PTH), PTH 1-84 and large C-PTH fragments in different stages of chronic kidney disease. Clin. Nephrol. 65 5 (2006) 328-334
22. Salomon R., Charbit M., Gagnadoux M.F., Niaudet P., Gao P., Cantor T., et al. High serum levels of a non-(1-84) parathyroid hormone (PTH) fragment in pediatric haemodialysis patients. Pediatr. Nephrol. 16 12 (2001) 1011-1014
23. Klaus G., Watson A., Edefonti A., Fischbach M., Ronnholm K., Schaefer F., et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr. Nephrol. 21 2 (2006) 151-159
24. Waller S.C., Ridout D., Cantor T., and Rees L. Parathyroid hormone and growth in children with chronic renal failure. Kidney Int. 67 6 (2005) 2338-2345
25. de Vernejoul M.C., Kuntz D., Miravet L., Gueris J., Bielakoff J., and Ryckewaert A. Bone histomorphometry in hemodialysed patients. Metab. Bone Dis. Relat. Res. 3 3 (1981) 175-179
26. Souberbielle J.C., Boutten A., Carlier M.C., Chevenne D., Coumaros G., Lawson-Body E., et al. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int. 70 2 (2006) 345-350
27. Cantor T., Yang Z., Caraiani N., and Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin. Chem. 52 9 (2006) 1771-1776
28. Sheth R.D., and Goldstein S.L. Comparison of 1-84 and intact parathyroid hormone assay in pediatric dialysis patients. Pediatr. Nephrol. 20 7 (2005) 977-981
29. Cantor T. Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management. Semin. Dial. 18 5 (2005) 359-364
30. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 69 11 (2006) 1945-1953